Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies von Koblish, Holly, Li, Yun-Long, Shin, Niu, Hall, Leslie, Wang, Qian, Wang, Kathy, Covington, Maryanne, Marando, Cindy, Bowman, Kevin, Boer, Jason, Burke, Krista, Wynn, Richard, Margulis, Alex, Reuther, Gary W, Lambert, Que T, Dostalik Roman, Valerie, Zhang, Ke, Feng, Hao, Xue, Chu-Biao, Diamond, Sharon, Hollis, Greg, Yeleswaram, Swamy, Yao, Wenqing, Huber, Reid, Vaddi, Kris, Scherle, Peggy

Volltext

Abstract 430: Pemigatinib, an FGFR inhibitor, overcomes resistance to KRASG12C inhibitors in mesenchymal-like NSCLC tumors von Favata, Margaret, Weber, Michael, Abdollahi, Angela, Roman, Valerie Dostalik, Farren, Matt, Gilmartin, Aidan, Kim, Sunkyu, Wee, Susan, Rios-Doria, Jonathan

Volltext

Abstract 1162: The evaluation of INCB059872, an FAD-directed covalent inhibitor of LSD1, in preclinical models of Ewing sarcoma von Roman, Valerie Dostalik, Ye, Min, Liu, Huiqing, Diamond, Melody, Chadderton, Antony, Lo, Yvonne, Liu, Xuesong M., Lu, Jin, He, Chunhong, Wu, Liangxing, Burn, Timothy, Wynn, Richard, Yao, Wenqing, Hollis, Gregory, Scherle, Peggy, Ruggeri, Bruce, Lee, Sang Hyun

Volltext